- Our research focus is on metabolic switch in BRAF/MEK inhibitors-resistant melanoma, and develop new strategies based on these mechanisms. We further study the common metabolic pathways seen in resistant melanoma and immune-suppressive cells.
- We focus on tumor metabolism in cisplatin-resistant (CR) lung cancer cells as well as the development of novel treatments. Our study demonstrated that TRX1 is the primary factor contributing to ROS elevation in CR cells. Moreover, we discover that CR cells activate the kynurenine (KYN) pathway to neutralize ROS and to evade immune surveillance.
- We investigate possible serum microRNAs as predictive markers for response to immune checkpoint inhibitor for hepatoma patients.